Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

9.795 +0.105 (+1.08%)

Delayed Quote Updated: 11:44 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

February 14, 2022

From ImmunityBio, Inc.

Via Business Wire

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

16 Stocks Moving in Tuesday's Pre-Market Session ↗

February 01, 2022

Gainers ObsEva SA (NASDAQ: OBSV) rose 22.2% to $1.87 in pre-market trading after the company announced a corporate update, including an increase in share capital on...

Via Benzinga

ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

January 31, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial ↗

January 19, 2022

ImmunityBio Inc (NASDAQ: IBRX) has revealed early results from its Phase 2 metastatic pancreatic cancer trial (QUILT 88), showing that patients' overall...

Via Benzinga

The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data ↗

January 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...

Via Benzinga

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival

January 18, 2022

From ImmunityBio, Inc.

Via Business Wire

The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week ↗

January 16, 2022

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...

Via Benzinga

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness

January 12, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Awarded Seminal Patent on Natural Killer Cells

January 04, 2022

From ImmunityBio, Inc.

Via Business Wire

61 Biggest Movers From Yesterday ↗

January 04, 2022

Gainers Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa...

Via Benzinga

Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture ↗

January 03, 2022

Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the...

Via Benzinga

45 Biggest Movers From Yesterday ↗

December 29, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares climbed 64.8% to close at $19.02 on Tuesday as traders circulated a social media post on a potential short squeeze. ShiftPixy...

Via Benzinga

25 Stocks Moving In Tuesday's Mid-Day Session ↗

December 28, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 64.6% to $18.99 as traders circulated a social media post on a potential short squeeze. Flotek Industries, Inc. (NYSE...

Via Benzinga

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder Cancer BLA Filing

December 20, 2021

From ImmunityBio, Inc.

Via Business Wire

63 Biggest Movers From Friday ↗

December 20, 2021

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...

Via Benzinga

52 Biggest Movers From Yesterday ↗

December 01, 2021

Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 30, 2021

Gainers Cumberland (NASDAQ:CPIX) stock...

Via Benzinga

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines

November 18, 2021

From ImmunityBio, Inc.

Via Business Wire

Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine ↗

November 08, 2021

Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19...

Via Benzinga

ImmunityBio to Present at the Jefferies London Healthcare Conference

November 04, 2021

From ImmunityBio, Inc.

Via Business Wire

Jim Cramer Advises Buying AZEK, Considers This Stock "Great Long-Term Story" ↗

October 29, 2021

On CNBC’s "Mad Money Lightning Round,&q...

Via Benzinga

ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial ↗

October 19, 2021

ImmunityBio Inc (NASDAQ: IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints ...

Via Benzinga

ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease

October 19, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date

October 13, 2021

From ImmunityBio, Inc.

Via Business Wire

National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy

October 04, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial

September 13, 2021

From ImmunityBio, Inc.

Via Business Wire

Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg ↗

September 08, 2021

Johnson & Johnson (NYSE: JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used in a mass trial of...

Via Benzinga

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗

September 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.